- Home
- NERV vs IHT Comparison
NERV vs IHT Comparison
Compare NERV & IHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- IHT
- Stock Information
- Founded
- NERV 2007
- IHT 1971
- Country
- NERV United States
- IHT United States
- Employees
- NERV N/A
- IHT N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- IHT Investment Bankers/Brokers/Service
- Sector
- NERV Health Care
- IHT Finance
- Exchange
- NERV Nasdaq
- IHT Nasdaq
- Market Cap
- NERV 14.6M
- IHT 12.6M
- IPO Year
- NERV 2014
- IHT N/A
- Fundamental
- Price
- NERV $3.78
- IHT $1.30
- Analyst Decision
- NERV Hold
- IHT
- Analyst Count
- NERV 1
- IHT 0
- Target Price
- NERV $4.00
- IHT N/A
- AVG Volume (30 Days)
- NERV 101.0K
- IHT 26.6K
- Earning Date
- NERV 11-05-2025
- IHT 12-15-2025
- Dividend Yield
- NERV N/A
- IHT 1.56%
- EPS Growth
- NERV N/A
- IHT N/A
- EPS
- NERV N/A
- IHT N/A
- Revenue
- NERV N/A
- IHT $7,463,789.00
- Revenue This Year
- NERV N/A
- IHT N/A
- Revenue Next Year
- NERV N/A
- IHT N/A
- P/E Ratio
- NERV N/A
- IHT N/A
- Revenue Growth
- NERV N/A
- IHT N/A
- 52 Week Low
- NERV $1.15
- IHT $1.26
- 52 Week High
- NERV $12.46
- IHT $4.24
- Technical
- Relative Strength Index (RSI)
- NERV 49.13
- IHT 32.30
- Support Level
- NERV $3.76
- IHT $1.26
- Resistance Level
- NERV $4.42
- IHT $1.36
- Average True Range (ATR)
- NERV 0.32
- IHT 0.07
- MACD
- NERV -0.09
- IHT -0.01
- Stochastic Oscillator
- NERV 25.93
- IHT 8.71
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About IHT InnSuites Hospitality Trust Shares of Beneficial Interest
InnSuites Hospitality Trust is a real estate investment trust. It is engaged in the ownership and operation of hotel properties. It owns and operates hotels, provides management services for hotels, and also provides trademark license services. The Trust is also involved in various operations incidental to the operation of hotels, such as the operation of restaurants, meeting/banquet room rentals, and the operation of a reservation system. It has one reportable segment Hotel Operations & Hotel Management Services.